Switch theme
Sign up to access all valuation multiples
Raia Drogasil SA is a large retail drug store operator in Brazil. The company is engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines. Its brands include Impulso, Amplimed, HealthBit, Stix, 4Bio, Drogasil, Raia and others.
2011
53.4K+
LTM Revenue $7.4B
LTM EBITDA $612M
$7.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Droga Raia has a last 12-month revenue of $7.4B and a last 12-month EBITDA of $612M.
In the most recent fiscal year, Droga Raia achieved revenue of $6.8B and an EBITDA of $547M.
Droga Raia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Droga Raia valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.9B | $6.8B | XXX | XXX | XXX |
| Gross Profit | $1.5B | $1.8B | XXX | XXX | XXX |
| Gross Margin | 26% | 26% | XXX | XXX | XXX |
| EBITDA | $480M | $547M | XXX | XXX | XXX |
| EBITDA Margin | 8% | 8% | XXX | XXX | XXX |
| Net Profit | $174M | $184M | XXX | XXX | XXX |
| Net Margin | 3% | 3% | XXX | XXX | XXX |
| Net Debt | $328M | $474M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Droga Raia's stock price is BRL 21 (or $4).
Droga Raia has current market cap of BRL 36.7B (or $6.4B), and EV of BRL 43.9B (or $7.6B).
See Droga Raia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.6B | $6.4B | XXX | XXX | XXX | XXX | $0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Droga Raia has market cap of $6.4B and EV of $7.6B.
Droga Raia's trades at 1.0x LTM EV/Revenue multiple, and 12.5x LTM EBITDA.
Analysts estimate Droga Raia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Droga Raia and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $7.6B | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 14.0x | XXX | XXX | XXX |
| P/E | 30.7x | XXX | XXX | XXX |
| P/E/Growth | 1.8x | XXX | XXX | XXX |
| EV/FCF | 69.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDroga Raia's NTM/LTM revenue growth is 9%
Droga Raia's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $30K for the same period.
Over next 12 months, Droga Raia's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Droga Raia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Droga Raia and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 17% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $30K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 24% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| Alibaba Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Droga Raia acquired XXX companies to date.
Last acquisition by Droga Raia was XXXXXXXX, XXXXX XXXXX XXXXXX . Droga Raia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Droga Raia founded? | Droga Raia was founded in 2011. |
| Where is Droga Raia headquartered? | Droga Raia is headquartered in Brazil. |
| How many employees does Droga Raia have? | As of today, Droga Raia has 53.4K+ employees. |
| Is Droga Raia publicy listed? | Yes, Droga Raia is a public company listed on BVMF. |
| What is the stock symbol of Droga Raia? | Droga Raia trades under RADL3 ticker. |
| When did Droga Raia go public? | Droga Raia went public in 1995. |
| Who are competitors of Droga Raia? | Similar companies to Droga Raia include e.g. MedPlus India, Pague Menos, Redcare Pharmacy, Oriola. |
| What is the current market cap of Droga Raia? | Droga Raia's current market cap is $6.4B |
| What is the current revenue of Droga Raia? | Droga Raia's last 12-month revenue is $7.4B. |
| What is the current EBITDA of Droga Raia? | Droga Raia's last 12-month EBITDA is $612M. |
| What is the current EV/Revenue multiple of Droga Raia? | Current revenue multiple of Droga Raia is 1.0x. |
| What is the current EV/EBITDA multiple of Droga Raia? | Current EBITDA multiple of Droga Raia is 12.5x. |
| What is the current revenue growth of Droga Raia? | Droga Raia revenue growth between 2023 and 2024 was 14%. |
| Is Droga Raia profitable? | Yes, Droga Raia is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
